about
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central n...
Read More
28.31
-1.99
(-6.57%)
917.1K
XNAS Volume
XNAS 10 Jul, 2026 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Bullish
Alumis Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..